BMRN

BioMarin Pharmaceutical Inc.

Healthcare · $11.5B market cap

Share price

$57.18

close of Oct 3, 2026

Fair value

$35.58

Sticker Price

Payback Price

$14.23

buy price

Overpriced

BMRN is Overpriced: at $57.18 it trades 61% above its fair value of $35.58. Its buy price (Payback Price) is $14.23, 75% below today's price. Business quality is strong: 4 of 5 key numbers clear the 10% bar.

How we valued it

Buffett Normalized. A profitable, growing business, so we project its earnings 10 years ahead and work out what that is worth today.

Business quality

4 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth12.4% a year✓

Equity per share growth11.6% a year✓

Sales growth15.4% a year✓

Free cash flow growth40.6% a year✓

Return on invested capital4.8%✗

Follow BMRN

Get notified when it reaches its buy price of $14.23. Free.

Create a free account

Superinvestors

4 of the investors we track hold BMRN. In Q2 2026, 1 added. Who we track

Howard Marks

Oaktree Capital Management · as of Q2 2026

$62.4B

64,025,000 shares

Dodge & Cox Funds

Dodge & Cox Funds · as of Q2 2026

$849.4M

14,844,930 shares

Viking Global Investors

Viking Global Investors · as of Q2 2026

$435.8M

7,616,563 shares

Torray Funds

Torray Funds · as of Q2 2026

$4.4M

77,705 shares

Moves in Q2 2026

Added: Howard Marks

Insider activity

Since Sep 2, 2026: no open-market purchases and 1 sale worth $1.2M. Why purchases matter

Sales

Davis George Eric

EVP, Chief Legal Officer · 2026-09-02

Sold

$1.2M

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme…

Biotechnology